Stockwatch: Headaches in neuroscience
This article was originally published in Scrip
Executive Summary
It has not been a good few months in the neuroscience therapeutic space and last week, in particular, saw the FDA reject one drug, and a clinical trial failure of another. GlaxoSmithKline set the stage for this theme last year when it announced its withdrawal from developing some neuroscience drugs; a shift in heritage for GSK as neuroscience was the therapeutic category that brought the company the blockbuster anti-depressant Seroxat/Paxil.
You may also be interested in...
Stock Watch: Risk And The Pharmaceutical Discount Rate
In contrast to the SEC’s view that public companies’ regulatory filings give investors all the information needed to make an investment decision, the discount rate used to value a company may not reflect all its risks.
Stock Watch: Pharma Businesses That Leave Consumer Behind
Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.